AXER-204 is under clinical development by ReNetX Bio and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect AXER-204’s likelihood of approval (LoA) and phase transition for Chronic Spinal Cord Injury took place on 19 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AXER-204 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AXER-204 is under development for the treatment of spinal cord injury, glaucoma, multiple sclerosis, optic neuritis, disorders with optic nerve injury, CNS axonal injuries and degenerative diseases. It consists of ectodomain of NgR1 fused to IgG1 and binds to Nogo-A, myelin-associated glycoprotein (MAG) and oligodendrocyte myelin glycoprotein (Omgp) ligands. It was also under development for the treatment of stroke.
ReNetX Bio overview
ReNetX Bio provide first-in-class therapeutics to treat injury/damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI), stroke, and glaucoma.
Quick View AXER-204 LOA Data
|Highest Development Stage|